A Study on Vattathiruppi Nei for the Treatment of Erumal in Children.
Phase 2
- Conditions
- Health Condition 1: J209- Acute bronchitis, unspecified
- Registration Number
- CTRI/2024/02/062700
- Lead Sponsor
- Dr T MONISHA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Upper and lower respiratory tract infection
Rhinitis
Nasobronchial allergy
Breathing difficulty
Dry cough or cough with phlegm
Sore throat
Exclusion Criteria
Children below 3 years
High grade fever
Severe asthma
Whooping cough
Pneumonia
Tuberculosis
Empyema
Paroxysmal noctural dyspnea
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Vattathiruppi Nei utilize to treat acute bronchitis in children?
How does Vattathiruppi Nei compare to standard-of-care treatments like bronchodilators and corticosteroids for J209 acute bronchitis in pediatric patients?
Are there specific biomarkers that could predict which children with acute bronchitis will respond best to Vattathiruppi Nei therapy?
What are the potential adverse events associated with Vattathiruppi Nei administration in children and how can they be managed?
What related compounds or combination therapies are being explored alongside Vattathiruppi Nei for treating ERUMAL (bronchitis) in children?